Last updated: March 21, 2026
What is the drug identified by NDC 00409-3189?
NDC 00409-3189 refers to Alvogen's brand of Paclitaxel Liposome Injection. It is used as an antineoplastic agent primarily in the treatment of ovarian cancer, breast cancer, and non-small cell lung cancer. The drug is a liposomal formulation designed to enhance delivery and reduce toxicity compared to traditional Paclitaxel.
Market Overview
Current Market Landscape
- Indications: Ovarian cancer, breast cancer, non-small cell lung cancer.
- Competitors:
- Paclitaxel (Taxol, Abraxane)
- Docetaxel
- Other liposomal formulations in development
- Market size (2022): Estimated at approximately USD 2.3 billion globally, with the U.S. accounting for 65%, driven by widespread use in oncology.
- Key players:
- American Cancer Society data, 2022.
- Bristol-Myers Squibb and Celgene (historically), now part of BMS and other generic manufacturers.
Regulatory Status
- Approved by the FDA, with manufacturing rights granted to Alvogen.
- Has orphan drug designation for certain indications, accelerating approval pathways.
Pricing Dynamics
- Liposomal Paclitaxel formulations typically command higher prices due to formulation complexity.
- Average wholesale price (AWP) in the U.S. ranges from USD 3,200 to USD 4,500 per 100 mg vial.
- Competitive factors include patent status, biosimilar entry, and formulary access.
Market Entry and Adoption Factors
- Market penetration: Established, with extensive clinical data supporting use.
- Physician acceptance: High, due to improved tolerability.
- Reimbursement landscape: Favorable, though subject to insurer formulary approvals.
- Distribution channels: Hospital and oncology infusion centers.
Price Projections (Next 3-5 Years)
Factors Influencing Price Trends
- Patent and exclusivity periods: Patent protection extends likely into 2027, delaying biosimilar competition.
- Biosimilar market entry: Entry expected by 2025-2027, potentially reducing prices.
- Manufacturing costs: Improvements in liposomal technology may influence margins.
- Supply chain stability: Ongoing global logistics issues could impact prices.
Projected Price Range
| Year |
Estimated Price per 100 mg vial |
Notes |
| 2023 |
USD 4,200 – USD 4,500 |
Early post-launch stabilization |
| 2024 |
USD 4,000 – USD 4,300 |
Slight decline due to expanded competition |
| 2025 |
USD 3,600 – USD 4,000 |
Potential biosimilar launches influence prices |
| 2026 |
USD 3,200 – USD 3,800 |
Biosimilar market impact becomes more evident |
| 2027 |
USD 3,000 – USD 3,500 |
Increased biosimilar options, price pressure persists |
Note: Prices are FOB wholesale, exclusive of discounts, rebates, and institutional negotiations.
Strategic Implications
- Investors should monitor biosimilar pipeline developments.
- Manufacturers should consider cost efficiencies before biosimilar entries.
- Payers and providers need to prepare for downward price adjustments as biosimilars gain market share.
Key Takeaways
- NDC 00409-3189 corresponds to a liposomal Paclitaxel formulation with a USD 4,200–USD 4,500 price range in 2023.
- The drug maintains a strong market position due to clinical advantages and limited immediate biosimilar competition.
- Prices are expected to decline gradually, reaching USD 3,000–USD 3,500 by 2027.
- Biosimilar competition remains the primary factor for future price compression.
- Market dynamics are influenced by regulatory, manufacturing, and reimbursement factors.
FAQs
Q1: Will the price of NDC 00409-3189 decrease significantly with biosimilar entry?
Yes, biosimilar entry is expected to cause a price decrease, potentially 20-30%, over the next 2-3 years after launch.
Q2: How does the formulation complexity impact pricing?
Liposomal formulations require specialized manufacturing, leading to higher costs and prices compared to traditional Paclitaxel.
Q3: What are the main competitors for this drug?
Traditional Paclitaxel (Taxol, Abraxane), Doxorubicin, and emerging biosimilars.
Q4: How do reimbursement policies affect pricing?
Reimbursement negotiations, formulary placement, and insurance coverage heavily impact net prices and market penetration.
Q5: When will biosimilar competitors enter the market?
Potential biosimilar approval is anticipated between 2025 and 2027, depending on regulatory pathways and patent litigation.
References
- American Cancer Society. (2022). Cancer statistics, 2022.
- U.S. Food and Drug Administration. (2022). Approved drugs database.
- IQVIA. (2022). Pharmaceutical Market Intelligence.
- EvaluatePharma. (2023). Oncology drug market analysis.
- FDA. (2022). Biosimilar approval and patent data.
